Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low-side effect therapies for idiopathic pain conditions. The company's award-winning flagship product, Nerivio®, is the first FDA-cleared smartphone-controlled prescribed wearable device for acute treatment of migraine, recently surpassed a quarter of a million treatments administered to date. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/29/22 | $45,000,000 | Series C |
aMoon Corundum Open Innovation Lightspeed Venture Partners LionBird New Rhein Healthcare Investors  Takoa Invest | undisclosed |
